Skip to content
10-Q/A

Quarterly Report

SALIX PHARMACEUTICALS LTD

0001193125-15-073260

← back to feed
Filed
Mar 2, 2015 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2014 · Nov 5, 2014 63.72M sh
Shares Diluted Q3 2014 · Sep 30, 2014 63.69M sh
Shares Diluted Q3 2014 · Sep 30, 2014 63.48M sh
Shares Diluted Q3 2014 · Sep 30, 2013 66.83M sh
Shares Diluted Q3 2014 · Sep 30, 2013 65.03M sh
Capex Q3 2014 · Sep 30, 2014 $13.38M
Capex Q3 2014 · Sep 30, 2013 $4.11M
Cash And Equivalents Q3 2014 · Sep 30, 2014 $422.58M
Cash And Equivalents Q3 2014 · Dec 31, 2013 $1.16B
Cash And Equivalents Q3 2014 · Sep 30, 2013 $817.73M
Cash And Equivalents Q3 2014 · Dec 31, 2012 $751.01M
Stockholders Equity restated Q3 2014 · Sep 30, 2014 $517.71M
Stockholders Equity restated Q3 2014 · Dec 31, 2013 $728.64M
Current Liabilities restated Q3 2014 · Sep 30, 2014 $1.6B
Current Liabilities restated Q3 2014 · Dec 31, 2013 $417.24M
Current Assets restated Q3 2014 · Sep 30, 2014 $1.49B
Current Assets restated Q3 2014 · Dec 31, 2013 $2.28B
Total Assets restated Q3 2014 · Sep 30, 2014 $4.82B
Total Assets restated Q3 2014 · Dec 31, 2013 $2.93B
Eps Diluted Q3 2014 · Sep 30, 2014 −$1.46
Eps Diluted restated Q3 2014 · Sep 30, 2014 −$2.00
Eps Diluted Q3 2014 · Sep 30, 2013 $0.71
Eps Diluted Q3 2014 · Sep 30, 2013 $1.40
Eps Basic Q3 2014 · Sep 30, 2014 −$1.46
Eps Basic restated Q3 2014 · Sep 30, 2014 −$2.00
Eps Basic Q3 2014 · Sep 30, 2013 $0.77
Eps Basic Q3 2014 · Sep 30, 2013 $1.48
Sga Expense Q3 2014 · Sep 30, 2014 $177.58M
Sga Expense restated Q3 2014 · Sep 30, 2014 $523.04M
Sga Expense restated Q3 2014 · Sep 30, 2013 $76.2M
Sga Expense restated Q3 2014 · Sep 30, 2013 $251.63M
Rd Expense Q3 2014 · Sep 30, 2014 $36.68M
Rd Expense restated Q3 2014 · Sep 30, 2014 $103.48M
Rd Expense restated Q3 2014 · Sep 30, 2013 $29.18M
Rd Expense restated Q3 2014 · Sep 30, 2013 $85.89M
Net Income Q3 2014 · Sep 30, 2014 −$93.11M
Net Income restated Q3 2014 · Sep 30, 2014 −$127.27M
Net Income Q3 2014 · Sep 30, 2013 $47.33M
Net Income Q3 2014 · Sep 30, 2013 $90.77M
Operating Income Q3 2014 · Sep 30, 2014 −$89.42M
Operating Income restated Q3 2014 · Sep 30, 2014 −$66.66M
Operating Income Q3 2014 · Sep 30, 2013 $76.31M
Operating Income Q3 2014 · Sep 30, 2013 $175.73M
Cost Of Revenue Q3 2014 · Sep 30, 2014 $86.11M
Cost Of Revenue restated Q3 2014 · Sep 30, 2014 $307.62M
Cost Of Revenue Q3 2014 · Sep 30, 2013 $42.9M
Cost Of Revenue Q3 2014 · Sep 30, 2013 $122.46M
Revenue Q3 2014 · Sep 30, 2014 $341.55M
Revenue restated Q3 2014 · Sep 30, 2014 $1.12B
Revenue Q3 2014 · Sep 30, 2013 $238.18M
Revenue Q3 2014 · Sep 30, 2013 $676.23M